13D/13G Filings - Pontifax Management 4 GP (2015) Ltd.

Real time Form 13D and 13G transaction reports:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
  • Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
Time period
Reported
DateTime
Transaction
Date
Type Company
Symbol
Filed By
Symbol
Shares Owned
% Owned
Shares Vs. Prev Report View
2025-04-18
5:10 pm
Purchase
2025-04-17 13D Keros Therapeutics, Inc.
KROS
Pontifax Management 4 GP (2015) Ltd. 4,787,331
11.800%
52,824increase
(+1.12%)
Filing
History
2024-11-05
10:55 am
Sale
2024-09-30 13G Nuvectis Pharma, Inc.
NVCT
Pontifax Management 4 GP (2015) Ltd. 288,873
1.500%
-628,527decrease
(-68.51%)
Filing
History
2024-02-06
08:47 am
Purchase
2023-12-31 13G Nuvectis Pharma, Inc.
NVCT
Pontifax Management 4 GP (2015) Ltd. 917,400
5.300%
917,400increase
(New Position)
Filing
History